Long Term Outcome of Patients with Acute Myelogenous Leukemia: The Role of Maintenance Therapy, Consolidation Therapy and the Predictive Value of Two in vitro Assays

References

• Rai K. R., Holland J. F., Glidewell O. J., Weinberg V., Brunner K., Obrecht J. P., Preisler H. D., Nawabi I. W., Prager D., Carey R. W., Cooper M. R., Haurani F., Hutchinson J. L., Silver R. T., Falkson G., Wiemik P., Hoagland C., Bloomfield C. D., James G. W., Gottlieb A., Ramanan S. V., Blom J., Nissen N. I., Bank A., Ellison R. R., Kung F., Henry P., McIntyre O. R., Kaan S. K. Treatment of Acute Myelocytic Leukemia: A Study of Cancer and Leukemia Group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Priesler H. D., Anderson K., Rai K., Cuttner J., Yates J., DuPre E., Holland J. F. The Frequency of Long Term Remission in Patients with Acute Myelogenous Leukemia Treated with Conventional Maintenance Chemotherapy: A Study of 760 Patients with a Minimal Follow-up time of 6 years. British Journal of Haematology 1989; 71: 189–194
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Winton E. F., Gordon D. S., Raney M. R., Go B., Meyer L. A Randomized Comparison of Postremission Therapy in Acute Myelogenous Leukemia: A Southeastern Cancer Study Group Trial. Blood 1984; 63: 1039–1045
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Begg C. B., Bennett J. M., Bozdech M., Kahn S. B., Weiler R., Glick J. H. A Randomized Study of the Efficacy of Consolidation Therapy in Adult Acute Nonlymphocytic Leukemia. Blood 1984; 63: 843–847
   PubMed Web of Science ®Google Scholar
• Priesler H. D., Kirshner J., Davis R., DuPre E., Richards Ill F., Hoagland H. D., Kopel S., Levy R. N., Carey R., Schulman P., Gottlieb A. J., McIntyre O. R., Cancer and Leukemia Group B. The Chemotherapy of Acute Nonlymphocytic Leukemia: A comparison of Three Remission Induction Regimens and an Evaluation of the Role of Prolonged Maintenance Chemotherapy. Blood 1987a; 69: 1441–1449
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Early A., Kirshner J., Brecher M., Freeman A., Rustum Y., Azarnia N., Priore R., Sandberg A. M., Block A. M., Browman G., Walker I., Benjer A., Miller K., D'Arrigo P., Doeblin T., Stein A., Bloom M., Logue G., Rustagi P., Barcos M., Larson R., Joyce R. Intensive Remission Consolidation Therapy in the Treatment of Acute Nonlymphocytic Leukemia. Journal of Clinical Oncology 1987b; 5: 722–730
   PubMed Web of Science ®Google Scholar
• Wolff S. N., Herzig R. H., Fay J. W., Phillips G. L., Lazarus H. M., Flexner J. M., Stein R. S., Greer J. P., Cooper B., Herzig G. P. High Dose Cytarabine and Daunorubicin as Consolidation Therapy for Acute Myeloid Leukemia in First Remission: Long Term Follow-up and Results. Journal of Clinical Oncology 1989; 7: 1260–1267
   PubMed Web of Science ®Google Scholar
• Champlin R., Gajewski J., Nimer S., Vollset S., Landaw E., Winston D., Schiller G., Ho W. Post-Remission Chemotherapy for Adults with Acute Myelogenous Leukemia. Improved Survival with High-dose Cytarabine and Daunorubicin Consolidation Treatment. Journal of Clinical Oncology 1990; 8: 1199–1206
   PubMed Web of Science ®Google Scholar
• Sauter C., Fopp M., Imbach P., Tschopp L., Berchtold W., Gratwohl A., Maurice P., von Fliedner V., Cavalli F. Acute Myelogenous Leukemia: Maintenance Chemotherapy after Early Consolidation Treatment Does Not Prolong Survival. Lancet. 1984; 1: 379–382
   PubMed Web of Science ®Google Scholar
• Buchner T., Urbanitz D., Hiddemann W., Ruhl H., Ludwig W. D., Fischer J., Aul H. C., Vaupel H. A., Kuse R., Zeile G., Nowrousian M. R., Konig H. J., Walter M., Wendt F. C., Sodomann H., Hossfeld D. K., von Paleske A., Loffler H., Gassmann W., Hellriegel K P., Fulle H. H., Lunscken Ch., Emmerich B., Pralle H., Pees H. W., Pfreundschuh M., Bartels H., Koeppen K M., Koppler H., Zurbor K H., Ranft K., Thiel E., Heinecke A. Intensified Induction and Consolidation with or without Maintenance Chemotherapy for Acute Myeloid Leukemia: Two Multicenter Studies of the German AML Cooperative Group. Journal of Clinical Oncology 1985; 3: 1583–1589
   PubMed Web of Science ®Google Scholar
• Moore M. A. S., Spitzer G., Williams N., Metcalf D., Buckley J. Agar Culture Studies in 127 Cases of Untreated Acute Leukemia: The Prognostic Value of Reclassification of Leukemia According to in vitro Growth Characteristics. Blood 1974; 44: 1–18
   PubMed Web of Science ®Google Scholar
• Spitzer G., Dicke K., Gehan E. A., Smith T., McCredie K. B., Barlogie B., Freireich E. A Simplified in vitro Classification for Prognosis in Adult Acute Leukemia: The Application of in vitro Results in Remission-Predictive Models. Blood 1976; 48: 795–807
   PubMed Web of Science ®Google Scholar
• Goldberg J., Tice D., Nelson D. A., Gottlieb A. J. Predictive Value of in vitro Colony and Cluster Formation in Acute Nonlymphocytic Leukemia. American Journal of Medical Sciences 1979; 111: 81–84
   Web of Science ®Google Scholar
• Preisler H. D., Azarnia N., Marinello M. Relationship of the Growth of Leukemic Cells in vitro to the Outcome of Therapy for Acute Nonlymphocytic Leukemia. Cancer Research 1984; 44: 1712–1719
   PubMed Web of Science ®Google Scholar
• Chou T. C., Arlin Z., Clarkson B. D., Philips F. S. Metabolism of 1-B-D Arabinofuranosylcytosine in Human Leukemic Cells. Cancer Research 1977; 37: 3561–3570
   PubMed Web of Science ®Google Scholar
• Rustum Y. M., Preisler H. D. Correlation between Leukemic Cell Retention of l-B-D-Arabinosylcytosine-5-triphosphate and Response to Therapy. Cancer Research 1979; 39: 42–49
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Rustum Y. M., Priore R. Relationship Between Leukemic Cell Retention of Cytosine Arabinoside Triphosphate and the Duration of Remission in Patients with Acute Myelocytic Leukemia. European Journal of Cancer and Clinical Oncology 1985; 21: 23–30
   PubMedGoogle Scholar
• Preisler H. D., Rustum Y. M., Azarnia N., Priore R. Abrogation of the Prognostic Significance of Low Leukemic Cell Retention of Cytosine Arabinoside Triphosphate by Intensification of Therapy and by Alteration in the Dose and Schedule of Administration of Cytosine Arabinoside. Cancer Chemotherapy and Pharmacology 1987c; 19: 69
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkette W., Dixon D., Keating M., McCreadie K., Freireich E. J. Variables Predicting Response to High Dose Cytosine Arabinoside Therapy in Patients with Refractory Acute Leukemia. Leukemia 1987; 1: 580–587
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposals for Classification of the Acute Leukemias. British Journal of Haematology 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Rustum Y., Henderson E. S., Bjornsson S., Creaven P. J., Higby D. J., Freeman A., Gailani S., Naeher C. Treatment of Acute Nonlymphotytic-Leukemia: Use of Anthracycline-Cytosine Arabinoside Induction Therapy and a Comparison of Two Maintenance Regimens. Blood 1979; 53: 455–464
   PubMed Web of Science ®Google Scholar